03/06/2026
【Healthcare is undergoing a $119 Billion revolution, and the ultimate competitive advantage isn’t just new drugs—it’s Real-World Data (RWD). 🧬📊】
For decades, patient data was trapped in isolated silos—divided between doctors, pharmacies, and insurers. Today, AI is breaking down those walls and turning fragmented information into actionable intelligence.
Two companies are currently rewiring this industry from completely different angles:
🔬 The Clinical Powerhouse: Tempus AI ($TEM)
Operating on the B2B side, Tempus connects over 3,000 US healthcare institutions to build a massive AI-powered library for cancer and heart disease data. Because of this scale, 95% of top pharma companies rely on Tempus to accelerate clinical trials and drug approvals.
📱 The Consumer Giant: Hims & Hers ($HIMS)
Bypassing traditional hospitals entirely, Hims goes straight to the consumer. With over 2.5 million subscribers using their platform for telehealth, weight loss, and wellness, they capture continuous, real-time data. This creates a goldmine for drug companies tracking long-term adherence and insurers modeling health risks.
🔗 The Flywheel Effect
Together, they illustrate the new “Data Flywheel” in action: diagnostic and telehealth data feeds AI insights, allowing pharma to develop better treatments while insurers seamlessly optimize their costs.
🌏The Asia Watchlist As the US scales, Asia’s data ecosystem is quietly unlocking. Keep your eyes on Ping An Good Doctor (1833.HK) leveraging its 400M+ consultations for AI diagnostics, WuXi AppTec (2359.HK) powering global pharma trials, and HK eHealth emerging as the critical gateway for unified public records.
Which approach do you think holds more long-term value: Clinical AI (Tempus) or Consumer Telehealth (Hims)? Let’s discuss below! 👇
💬 DM us to build a data-driven PR strategy that scales your health-tech brand.
👉 Follow .pr for actionable tech trends and PR insights!
